Based on the results described here, future therapeutic strategies should consider the use of RAC1 inhibitors in combination with existing anti-cancer therapies, to reduce tumor development and metastasis, as well as to decrease resistance to anti-cancer therapies. Here, RAC1 is linked to cancer.